Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)
Conditions
Bladder Cancer · Bladder Cancer Recurrent · Neoplasm Recurrence · Urothelial Carcinoma Bladder · Urothelial Carcinoma Recurrent · Non-Invasive Bladder Urothelial Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Site 05, Vancouver, British Columbia, Canada
Contact: Study coordinator (Principal Investigator)Site 04, Kingston, Ontario, Canada
Contact: Study coordinator (Principal Investigator)Site 01, Toronto, Ontario, Canada
Contact: Study coordinator (Principal Investigator)Site 02, Toronto, Ontario, Canada
Contact: Study coordinator (Principal Investigator)Site 08, Toronto, Ontario, Canada
Site 10, Montreal, Quebec, Canada
Contact: Study coordinator (Principal Investigator)
Study leads
Girish S Kulkarni, MD
Principal Investigator
Princess Margaret Cancer Centre, 700 University Ave, 6-824 Toronto, ON, M5G 1X6, Canada
Alexandre R Zlotta, MD, PhD, FRCSC
Principal Investigator
Mount Sinai Hospital, 600 University Avenue, Toronto, ON, M5G 1X5